Business Description
Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.
Business History
Price Overview
Last updated: Jun 27, 2026 10:02am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 4.80
Total Equity: $1.26B
Shares: 32,604,000
Total Debt: $179.14M
Cash: $74.57M
EBITDA: $254.44M
Total Debt: $179.14M
Cash: $74.57M
Revenue: $1.04B
Revenue: $1.04B
Revenue: $1.04B
Total Equity: $1.26B
Tax Rate: 22.2%
Equity: $1.26B
Total Debt: $179.14M
Cash: $74.57M
Current Liabilities: $176.38M
Long-Term Debt: $175.32M
Total Debt: $179.14M
Total Equity: $1.26B
Shares: 32,604,000
Shares: 32,604,000
CapEx: -$43.49M
Shares: 32,604,000
Stock Price: $171.22
Net Income: $154.85M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 21, 2026 7:42pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $799.0M | $942.4M | $922.4M | $953.7M | $1.0B |
| Cost of Revenue | $555.8M | $661.9M | $620.4M | $617.5M | $666.5M |
| Gross Profit | $243.2M | $280.5M | $302.1M | $336.2M | $370.6M |
| Operating Expenses | $115.7M | $135.3M | $142.9M | $153.3M | $152.3M |
| Operating Income | $127.5M | $145.2M | $159.2M | $182.9M | $218.3M |
| Net Income | $96.1M | $105.4M | $108.5M | $128.5M | $154.8M |
| EBITDA | $176.6M | $195.9M | $214.8M | $231.0M | $254.4M |
| EPS | $2.98 | $3.29 | $3.38 | $3.97 | $4.80 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:42pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $103.2M | $66.6M | $64.4M | $49.5M | $74.6M |
| Total Current Assets | $322.2M | $335.8M | $314.2M | $313.8M | $365.6M |
| Total Assets | $1.2B | $1.6B | $1.6B | $1.6B | $1.7B |
| Current Liabilities | $143.8M | $140.0M | $148.5M | $157.7M | $176.4M |
| Long-Term Debt | $108.6M | $440.6M | $309.6M | $190.0M | $175.3M |
| Total Liabilities | $322.3M | $686.2M | $543.2M | $425.5M | $450.1M |
| Total Equity | $877.0M | $938.3M | $1.1B | $1.1B | $1.3B |
| Retained Earnings | $732.1M | $814.5M | $897.5M | $997.5M | $1.1B |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:42pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $160.5M | $138.5M | $183.8M | $182.0M | $216.6M |
| Capital Expenditure | -$37.4M | -$50.3M | -$37.9M | -$35.7M | -$43.5M |
| Free Cash Flow | $123.1M | $88.2M | $145.9M | $146.3M | $173.1M |
| Acquisitions (net) | $318,000 | -$365.8M | -$1.5M | -$24.2M | $-48,999 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$35.2M | -$35.4M | -$4.5M | -$5.7M | -$107.6M |
| Net Change in Cash | $18.7M | -$36.7M | -$2.1M | -$14.9M | $25.1M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 8:57am (1h ago)| Metric | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| Revenue |
$1.1B $1.1B – $1.1B
|
$1.2B $1.1B – $1.2B
|
$1.2B $1.2B – $1.2B
|
$1.3B $1.3B – $1.3B
|
| EBITDA |
$315.2M $312.4M – $321.0M
|
$331.9M $326.2M – $343.4M
|
$353.6M $353.6M – $353.6M
|
$371.0M $364.7M – $380.2M
|
| Net Income |
$169.6M $167.0M – $176.3M
|
$178.6M $175.2M – $184.1M
|
$0 | $0 |
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:42pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +17.9% | -2.1% | +3.4% | +8.8% |
| Gross Profit Growth | +15.3% | +7.7% | +11.3% | +10.2% |
| Operating Income Growth | +13.9% | +9.6% | +14.9% | +19.4% |
| Net Income Growth | +9.6% | +3.0% | +18.4% | +20.5% |
| EBITDA Growth | +10.9% | +9.7% | +7.5% | +10.2% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 8:57am (1h ago)All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-04-01 | Gilson Erin Leigh | 0.00 | $0.00 | $0 | |
| 2026-04-01 | Gilson Erin Leigh | 0.00 | $0.00 | $0 | |
| 2020-02-13 | Gilson Erin Leigh | 1,000.00 | $84.09 | $84,090 | |
| 2021-02-13 | Gilson Erin Leigh | 900.00 | $111.94 | $100,746 | |
| 2021-12-22 | Gilson Erin Leigh | 1,500.00 | $113.24 | $169,860 | |
| 2022-02-11 | Gilson Erin Leigh | 600.00 | $119.13 | $71,478 | |
| 2024-02-08 | Gilson Erin Leigh | 600.00 | $138.09 | $82,854 | |
| 2025-02-08 | Gilson Erin Leigh | 600.00 | $143.43 | $86,058 | |
| 2023-02-10 | Gilson Erin Leigh | 600.00 | $138.07 | $82,842 | |
| 2019-02-15 | Gilson Erin Leigh | 360.00 | $74.57 | $26,845 | |
| 2026-02-11 | van Gunsteren Job Leonard | A-Award | 1,345.00 | $0.00 | $0 |
| 2026-02-11 | van Gunsteren Job Leonard | F-InKind | 756.00 | $178.68 | $135,082 |
| 2026-02-12 | van Gunsteren Job Leonard | F-InKind | 58.00 | $177.49 | $10,294 |
| 2026-02-11 | van Gunsteren Job Leonard | A-Award | 430.00 | $0.00 | $0 |
| 2026-02-11 | van Gunsteren Job Leonard | A-Award | 1,600.00 | $178.68 | $285,888 |
| 2026-02-11 | Reid Martin Luther | A-Award | 2,359.00 | $0.00 | $0 |
| 2026-02-11 | Reid Martin Luther | F-InKind | 1,085.00 | $178.68 | $193,868 |
| 2026-02-12 | Reid Martin Luther | F-InKind | 116.00 | $177.49 | $20,589 |
| 2026-02-11 | Reid Martin Luther | A-Award | 940.00 | $0.00 | $0 |
| 2026-02-11 | Reid Martin Luther | A-Award | 3,400.00 | $178.68 | $607,512 |
Dividend History (Last 20)
Last updated: Jun 21, 2026 7:42pm (5d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2025-12-23 | $0.96 | 2025-12-09 | 2025-12-23 | 2026-01-20 |
| 2024-12-26 | $0.87 | 2024-12-10 | 2024-12-26 | 2025-01-17 |
| 2023-12-26 | $0.79 | 2023-12-04 | 2023-12-27 | 2024-01-19 |
| 2022-12-23 | $0.71 | 2022-12-06 | 2022-12-27 | 2023-01-20 |
| 2021-12-27 | $0.64 | 2021-12-16 | 2021-12-28 | 2022-01-21 |
| 2020-12-24 | $0.58 | 2020-12-17 | 2020-12-28 | 2021-01-22 |
| 2019-12-27 | $0.52 | 2019-12-18 | 2019-12-30 | 2020-01-17 |
| 2018-12-24 | $0.47 | 2018-12-12 | 2018-12-26 | 2019-01-18 |
| 2017-12-26 | $0.42 | 2017-12-13 | 2017-12-27 | 2018-01-19 |
| 2016-12-22 | $0.38 | 2016-12-15 | 2016-12-27 | 2017-01-20 |
| 2015-12-23 | $0.34 | 2015-12-18 | 2015-12-28 | 2016-01-21 |
| 2014-12-24 | $0.30 | 2014-12-22 | 2014-12-29 | 2015-01-27 |
| 2013-12-19 | $0.26 | 2013-12-13 | 2013-12-23 | 2014-01-21 |
| 2012-12-12 | $0.22 | 2012-12-04 | 2012-12-14 | 2012-12-21 |
| 2011-12-12 | $0.18 | 2011-12-09 | 2011-12-14 | 2012-01-16 |
| 2010-12-17 | $0.15 | 2010-12-14 | 2010-12-21 | 2011-01-20 |
| 2009-12-28 | $0.11 | 2009-12-14 | 2009-12-30 | 2010-01-20 |
| 2008-12-18 | $0.11 | 2008-12-12 | 2008-12-22 | 2009-01-20 |
| 2007-12-18 | $0.11 | 2007-12-07 | 2007-12-20 | 2008-01-18 |
| 2006-12-27 | $0.09 | 2006-12-12 | 2006-12-29 | 2007-01-19 |
Narrative Economics
market-narrative step).